The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio ...

This major step unlocks a new milestone payment of €26.5 million under our Licensing and Collaboration Agreement with Ipsen 2, due upon pricing and reimbursement of Iqirvo® (elafibranor) in three ...

TrialWire is the AI and algorithm-powered patient-recruitment and enrollment platform, purpose-built on Salesforce Health Cloud to guarantee best-in-class data and IP security.

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to ...

Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors.

Pending data from the Phase 1 trial, Oruka plans to initiate a Phase 2 study of ORKA-002 in moderate-to-severe psoriasis in the first half of 2026. The planned study design will evaluate the safety ...

Event: William Blair 45th Annual Growth Stock Conference Date: Tuesday, June 3, 2025 Time: 7:20 a.m. PST / 9:20 a.m. CST A live and archived webcast of the presentation will be available in the ...

The awards were granted under the Vaxart, Inc. 2024 Inducement Award Plan as an employment “inducement award” pursuant to Nasdaq Listing Rule 5635 (c) (4). The Inducement Award Plan is used ...

RxSight’s management is scheduled to participate in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live and archived webcast of the presentation will ...

Segra International (“Segra”), a global leader in cannabis agriculture technology, proudly announces its strategic amalgamation with Klonetics Plant Science Inc., a licensed cannabis nursery and ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug ...

SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (“Cooper”) (Nasdaq: COO), a leading medical device company, published its 2024 Sustainability Report. The report showcases the ...